Companies: 10,795·Total market cap: $144.5T

Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.

CDTXNASDAQHealthcare

$221.38

+$0.00(+0.00%)

Market Cap$5.6B

P/E Ratio—

52W High$221.42

52W Low$15.22

Avg Volume1.4M

Open$221.38

Beta1.53

Cidara Therapeutics, Inc. (CDTX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CDTX · net income · updated Jun 8, 2026

Core profitability metrics

CDTX · net income · margin · TTM · CAGR

Net income was −$169.8M for FY2024 (fiscal year ending 2024-12-31), down 640.6% year-over-year. Net profit margin was -13319.8%.

FY2024 Net Income−$169.8M▼ -640.6% YoY

Trailing 12M (TTM)−$184.7Mtrailing 4 quarters sum

Net Profit Margin< −999%−$169.8M ÷ $1.3M

YoY Change-640.6%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · CDTX net income history · CDTX profit margin

Annual net income data

CDTX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2024Loss−$169.8M▼ 640.6%-13319.8%$1.3M

FY2023Loss−$22.9M▲ +31.7%-98.5%$23.3M

FY2022Loss−$33.6M▲ +20.9%-52.1%$64.4M

FY2021Loss−$42.5M▲ +41.1%-85.7%$49.6M

FY2020Loss−$72.1M▼ 75.5%-597.6%$12.1M

Net income vs peers (Healthcare)

CDTX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Cidara Therapeutics, Inc.YOU

CDTX

−$169.8M-640.6%-13319.8%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Cidara Therapeutics, Inc. (CDTX) reported net income of −$169.8M for FY2024 (fiscal year ending 2024-12-31), down 640.6% year-over-year. The net profit margin was -13319.8% — meaning the company kept $-133.20 of every dollar of revenue as profit.

Cidara Therapeutics, Inc. has not yet achieved annual profitability based on available data (13 fiscal years). The company has reported net losses across all available periods.

Cidara Therapeutics, Inc.'s net profit margin was -13319.8% for FY2024, based on the latest annual results.

Investors sometimes search for "Cidara Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from CDTX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CDTX net income · 4 questions

Cidara Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $169.8M for FY2024.

is CDTX profitabledoes CDTX make a profitCDTX profitabilityCDTX profitable company

▸ Source: FMP /income-statement · GAAP · Cidara Therapeutics, Inc. · Cidara Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026